Home
overview

SMi are pleased to announce their second annual ADC summit 2013. This event has a world leading speaking faculty that will provide the latest insights on antibody-drug conjugates.

Antibody drug conjugates are at the forefront of targeted chemotherapy for the treatment of cancer. Anticipated use of ADCs over the next 5-10 years in set to increase by 40-50% specifically within cancer research. This huge surge in programme is down to highly succesful clinical trials and results that indicate a leap forward in targeted therapeutic delivery, with monoclonal antibodies being used as a springboard for this huge success.

A unique event held in London, let ADC 2013 show you how and where the latest technologies and clinical data have transformed this field. Hear from recent advances in conjugate chemistry, target selection, novel payload deliveries, future ADC pipelines and regulatory issues.

The event will be presented via case studies by those who are working within the latest patents on new molecules. See the latest clinical data on ADCs pushing through trials in I-IV and methods to select antibody platforms that will be most effective against specific diseases.

  • The U.Ks only dedicated event on the area. With world leading research being carried out in the U.K. see first hand exactly where the pitfalls and advantages are of developing an anti-body drug conjugate.
  • Expert speakers in the lead of their field from big pharma and biotech companies.
  • Case study driven - Unadulterated data on ADC development
  • CMC strategies for ADCs issues in manufacture processes

Drug Discovery
Biologics
Biologics generation
Antibody research
Antibody conjugate development
Antibody conjugate discovery
Biomelecular Research
Genomics Research
Antibody Engineering
Protein Sciences
Protein Technologies
Bioanalyticcs
Cell Assays
Molecular Cell Biology
Pharamacology Regulatory Affairs
CMC

Alaska TSA Aviation Operations; AMRDEC; ANNISTON ARMY DEPOT; arsenal research; BAE SYSTEMS,; Battelle; Boeing-Tactical Aircraft St. Louis; College of Southern Nevada; Discover Wisconsin; ECC; GlaxoSmithKline; Hermann Pipersberg Jun G Mb H; Hexing Electrical Co Ltd; HTG Technologies; Hutchison 3g; I B M; I C S A (India) Ltd; Lansdale Semiconductor; M I T; Medway Council; Ministry Of Defence - Directorate General Of Armaments; Public Works And Government Services Canada; Qalhat Lng; South Hook Gas Company Ltd; Sprout Consulting; The Goyak Group; The Tolliver Group; Troy 7; University of Strathclyde; Us Air Forcee Academy; Vectors Inc;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Lutz Jermutus

Lutz Jermutus, Senior Director, Technology, MedImmune

9:10 New opportunities for antibodies in enabling small molecule discovery

Alastair Lawson

Alastair Lawson, VP Structural Biology, UCB

  • Antibodies are successfully addressing modulation of protein-protein interactions in the clinic; enabling the discovery of small molecules "chemosuperiors"
  • Antibodiesare being used to define specific conformations of proteins providing new unexpected opportunities for intervention with small molecules
  • Small molecule fragment screening against antibody-constrained targets offers the prospect of discovering new chmical entities, the approach is well suited to small molecule discovery modulating protein-protein interactions
  • 9:50 Targeting solid tumors with Antibody-Directed Immunoliposomal Therapeutics

    Daryl Drummond

    Daryl Drummond, Senior Director, Nanotherapeutics, Merrimack Pharmaceuticals

  • Engineering considerations for development of targeted site-specific and sustained release of small molecule drugs
  • Contrast and complimentary strategy to standard ADC formats
  • Recent preclinical and clinical results
  • 10:30 Morning Coffee

    11:00 Development of AGS15E, a novel antibody drug conjugate (using Monomethyl Auristatin E) Targeting SLITRK6 for the treatment of bladder cancer

    Kendall Morrison

    Kendall Morrison, Director of Protein Technologies, Agensys (an affiliate of Astellas)

  • Discovery and validation of SLITRK6 as a novel cancer target
  • Antibody discovery process
  • Pre-clinical evaluation and ADC development
  • 11:40 Building traceless Antibody-Drug Conjugates

    Goncalo Bernardes

    Goncalo Bernardes, Principal Investigator & Royal Society University Research Fellow, Instituto de Medicina Molecular, Lisbon & Department of Chemistry, University of Cambridge

  • Introductions
  • Site specific modification of traceless ADCs
  • Site specific modification of innovative ADCs
  • Case study
  • 12:20 Networking Lunch

    13:50 Targeting tumor antigens with armed antibodies: Matching the tool to the job

    Robert Hollingsworth

    Robert Hollingsworth, Senior Director, Medimmune Inc

  • Identification and evaluation of tumor - associated antigens
  • Different armed antibody technologies used by MedImmune
  • Approaches to selecting the right armed antibody technology for individual tumor-associated antigens
  • 14:30 Antibody-Pyrrolobenzodiazepine (PBD) Conjugates

    John Hartley

    John Hartley, Head of Biology, Spirogen

  • Design and development of PBD-ADCs
  • Advantages of PBDs as ADC warheads
  • Case study and issues moving forward
  • 15:10 Afternoon Tea

    15:40 Antibody-Directed Phototherapy (ADP) and Beyond

    Mahendra Deonarain

    Mahendra Deonarain, Honorary Reader in Antibody Technology , Imperial College London

  • Use of optimised antibody fragments
  • Light-activated and non-light activated drugs
  • Strategies for bio-conjugation
  • 16:20 Cancer testis antigens and other intranuclear targets for radioimmunotherapy

    Katherine Vallis

    Katherine Vallis, Professor of Experimental Radiotherapeutics, University of Oxford

  • Investigation of novel targets, including cancer testis antigens for radioimmunotherapy
  • Development of nano-scale microdosimetry systems for radioimmunotherapy
  • Case study
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Mahendra Deonarain

    Mahendra Deonarain, Honorary Reader in Antibody Technology , Imperial College London

    9:10 Phase I clinical programme for the novel ADC AGS-16M8F/16C3F

    Anna Butturini

    Anna Butturini, Associate Medical Director, Agensys (an affiliate of Astellas)

  • Target selection - AGS-16 hits a single transmembrane antigen (EPP3 / CD203C ( ectonucleotide pyrophophatase/phosphodiesterase3))
  • AGS-16M8F/16C3F: IgG2 - Drug conjugate - Fully human from XenoMouse technology
  • Developing AGS-16M8F/16C3F - A unique antibody with significant preclinical activity in metastatic renal cell carcinoma
  • Case study phase I trial experience
  • 9:50 Ensuring a successful regulatory strategy to enable clinical development of ADCs: considerations for novel therapies and biobetters

    Natalie Thomas

    Natalie Thomas, Regulatory Affairs Project Manager, Era Consulting (UK) Limited

  • Regulatory requirements for commencement of clinical development of biobetters and novel ADCs
  • Strategic regulatory considerations for the development of ADCs
  • Case studies reviewing the successes and failures of ADCs to date, and lessons to be learned
  • 10:30 Morning Coffee

    11:00 DeBouganin: A next generation toxin payload for oncology

    Glen MacDonald

    Glen MacDonald, CSO, Viventia Bio Inc.

  • Review of the successful de-immunization of the plant cytotoxin Bouganin
  • Provide an overview of the advantages of deBouganin relative to other payload technologies
  • Comparative assessment of deBouganin vs. current ADC payloads
  • 11:40 Producing better antibody-drug conjugates using ThioBridge™ conjugation

    Anthony Godwin

    Anthony Godwin, Director of Science & Technology, PolyTherics

  • Efficient and predictable site-specific conjugation to disulfide bridges
  • Reduced heterogeneity as drug antibody ratio (DAR) limited to a maximum of 4
  • Ability to tailor the linker to the antibody and payload combination
  • In vitro and in vivo data for mAb and Fab confirms specific binding and activity
  • 12:20 Networking Lunch

    13:50 Novel linker-drugs for ADCs

    Thomas  Pillow

    Thomas Pillow, Scientist, Genentech

  • Developing a linker-drug toolbox
  • Drugs with diverse mechanisms of action
  • Case study
  • 14:30 Discovery and preclinical evaluation of novel antibody-maytansinoid ADC product candidates

     

  • Rationale for target selection and strategies for target validation
  • Discovery and selection of optimal antibodies
  • Approaches for preclinical assessment of maytansinoid ADCs
  • Yulius Setiady

    Yulius Setiady, Principle Scientist, Discovery Research, Immunogen

    15:10 Afternoon Tea

    15:40 Panel Discussion: The future of ADCs

  • The most important factors moving forward
  • The latest improvements on current ADC research
  • Recent roadbloacks and challenges
  • Lutz Jermutus

    Lutz Jermutus, Senior Director, Technology, MedImmune

    Kerry Chester

    Kerry Chester, Professor, University College London

    16:30 Intellectual property: colocation, synergy and ADCs

    Tony Maschio

    Tony Maschio, Partner, Maschio & Soames LLP

     

  • Are all antibody-drug conjugates obvious?
  • What is synergy?
  • Approaches to protecting ADCs
  • Strategies for attacking ADC patents
  • 17:10 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Alastair Lawson

    Alastair Lawson

    VP Structural Biology, UCB
    John Hartley

    John Hartley

    Head of Biology, Spirogen
    Kendall Morrison

    Kendall Morrison

    Director of Protein Technologies, Agensys (an affiliate of Astellas)
    Robert Hollingsworth

    Robert Hollingsworth

    Senior Director, Medimmune Inc
    Thomas  Pillow

    Thomas Pillow

    Scientist, Genentech

    Alastair Lawson

    VP Structural Biology, UCB
    Alastair Lawson

    Anna Butturini

    Associate Medical Director, Agensys (an affiliate of Astellas)
    Anna Butturini

    Anthony Godwin

    Director of Science & Technology, PolyTherics
    Anthony Godwin

    Daryl Drummond

    Senior Director, Nanotherapeutics, Merrimack Pharmaceuticals
    Daryl Drummond

    Glen MacDonald

    CSO, Viventia Bio Inc.
    Glen MacDonald

    Goncalo Bernardes

    Principal Investigator & Royal Society University Research Fellow, Instituto de Medicina Molecular, Lisbon & Department of Chemistry, University of Cambridge
    Goncalo Bernardes

    John Hartley

    Head of Biology, Spirogen
    John Hartley

    Katherine Vallis

    Professor of Experimental Radiotherapeutics, University of Oxford
    Katherine Vallis

    Kendall Morrison

    Director of Protein Technologies, Agensys (an affiliate of Astellas)
    Kendall Morrison

    Kerry Chester

    Professor, University College London
    Kerry Chester

    Lutz Jermutus

    Senior Director, Technology, MedImmune
    Lutz Jermutus

    Mahendra Deonarain

    Honorary Reader in Antibody Technology , Imperial College London
    Mahendra Deonarain

    Matthias Machacek

    Engineering Cluster Head, Novartis
    Matthias Machacek

    Natalie Thomas

    Regulatory Affairs Project Manager, Era Consulting (UK) Limited
    Natalie Thomas

    Robert Hollingsworth

    Senior Director, Medimmune Inc
    Robert Hollingsworth

    Thomas Pillow

    Scientist, Genentech
    Thomas  Pillow

    Tony Maschio

    Partner, Maschio & Soames LLP
    Tony Maschio

    Yulius Setiady

    Principle Scientist, Discovery Research, Immunogen
    Yulius Setiady

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.